Home | TESTOSTERONE 2-page summation | high testosterone 40% lower death rate | Prostate cancer not promoted by testosterone | DHEA cheap legal popular steroid | Viagra & Erectal Dysfunction | Why Testosterone is Cardiovascular Protective | TESTOSTERONE-CONCISE NOTES | TESTOSTERONE--EXTENSIVE NOTES | Pharmacology textbook, chapter on TESTOSTERONE | Methods of Testosterone Supplementation | Testosterone for Women? | TTT GOOD FOR THE BRAIN--2 studies | MALE-MENOPAUSE-2ND ARTICLE | MALE MENOPAUSE | DOUBTS ON TTT & ANDROSTENE | OVER-THE-COUNTER-SOLUTION | HOT NUTS: THE CONSEQUENCES | Oral hGH, what works? | HGH-HYPE & FACTS | HGH-POSITIVE FINDINGS--HARVARD | TESTOSTERONE NOT LINKED TO PROSTATE CANCER--latest study shows | Cialis better than Viagra | VIAGRA SAFE | circumcision reduces HIV risk 60% | Prostate Disease | Prostate biopsy, PSA test, prostatectomy--Urology textbook | Prostate cancer and blocking testosterone | LINKS

MALE HORMONES

TESTOSTERONE NOT LINKED TO PROSTATE CANCER--latest study shows

      Contrary to accepted wisdom.  It has been long assumed that testosterone stimulates the growth of prostate cancer; just like estrogen does for breast cancer.  It is standard procedure to proscribe a drug that blocks testosterone (pharmaceutical castration), the equivalent is done to women with breast cancer.  Both assumptions about hormones are false. Will it stimulate the progression of pre-cancerous microscopic tumors into cancer? This study addresses that question and answers it in the negative.  Testosterone does not accelerate the transformation of these pre-cancerous tumors into cancer, though low testosterone does.  The study below is of the serum levels of testosterone related androgens and their metabolites.  The serum levels of those with prostate cancer and those without were essentially the same.  More recent studies show a positive effect of testosterone as to prevent and slowing the progression of prostate cancer.  The Bottom section has links to those articles, and a like set on estrogen and breast cancer—jk. 

For articles on the referred to articles on hormones go to http://healthfully.org/rc/index.html

Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies

 

Eaton NE, Reeves GK, Appleby PN, Key TJ.

 

Imperial Cancer Research Fund, Cancer Epidemiology Unit, Radcliffe Infirmary, Oxford, UK.

 

This paper presents a quantitative review of the data from eight prospective epidemiologieal studies, comparing mean serum concentrations of sex hormones in men who subsequently developed prostate cancer with those in men who remained cancer free. The hormones reviewed have been postulated to be involved in the aetiology of prostate cancer: androgens and their metabolites testosterone (T), non- SHBG-bound testosterone (non-SHBG-bound T), di-hydrotestosterone (DHT), androstanediol glucuronide (A-diol-g), androstenedione (A-dione), dehydroepiandrosterone sulphate (DHEAS), sex hormone binding globulin (SHBG), the oestrogens, oestrone and oestradiol, luteinizing hormone (LH) and prolactin. The ratio of the mean hormone concentration in prostate cancer cases to that of controls (and its 95% confidence interval (CI)) was calculated for each study, and the results summarized by calculating the weighted average of the log ratios. No differences in the average concentrations of the hormones were found between prostate cancer cases and controls, with the possible exception of A-diol-g which exhibited a 5% higher mean serum concentration among cases relative to controls (ratio 1.05, 95% CI 1.00-1.11), based on 644 cases and 1048 controls. These data suggest that there are no large differences in circulating hormones between men who subsequently go on to develop prostate cancer and those who remain free of the disease. Further research is needed to substantiate the small difference found in A-diol-g concentrations between prostate cancer cases and controls.

 

Publication Types:

•  Meta-Analysis

 

Below are the sections from the articles on estrogen and on testosterone.  These articles show that every elderly person ought to be taking replacement, natural hormones.  The links prove this point.  Again the effects of corporate marketing science are exposed.  The links on these two sections on cancer and hormones show that marketing science functions to support profits. 

For the entire articles go to http://healthfully.org/rc/index.html and find out why every elderly person ought to maintain a youthful hormone profile.  

Prostate cancer:  Low levels of TTT is associated with both prostate cancer and aggressive prostate cancer, while normal level are not associated with disease progression.  “In our study patients with prostate cancer and low free TTT had more extensive disease.  In addition, all men with a biopsy Gleason score of 8 or greater had low serum free testosterone. This finding suggests that low serum free testosterone may be a marker for more aggressive disease.”  The practice of block TTT for those with prostate cancer cannot be justified given these findings.  Similar find for breast cancer and low estrogen—both are counter to prevailing opinion. 

 

 Decreases breast cancer 73% using estradiol:   “in breast cancer (10 in treated group v 17 in control group).”   HRT after & also during breast cancer greatly increases survival; “also ratio 0.28.”  “MPA increases the risk of breast cancer” (what PhARMA uses to attach all HRT).  Other progestins, especially MPA, increase risk.  Contrary to PhARMA’s thought leaders, estradiol reduces risk.